Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
AssigneeBiPar Sciences, Inc.
InventorsValeria Ossovskaya, Charles Bradley, Barry Sherman
Life of this patent
Estimating the term…
Abstract
In one aspect, the present invention provides a composition and a kit comprising a combination of topoisomerase inhibitor and PARP inhibitor for treatment of cancer. In another aspect, the invention provides a method of treating cancer comprising administering to a subject a combination of topoisomerase inhibitor and PARP inhibitor. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase and a topoisomerase, as well as providing formulations and modes of administering such compositions.
Claims39
A method of treating a cancer, comprising administering to a patient an effective amount of a combination of a topoisomerase inhibitor and a PARP inhibitor of formula (Ia)
- wherein R1, R2, R3, R4, and R5 are, independently selected from the group consisting of hydrogen, hydroxy, amino, nitro, iodo, bromo, fluoro, chloro, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl, and phenyl, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents are always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts, solvates, isomers, tautomers, metabolites, analogs, or prodrugs thereof
- wherein the cancer is not breast cancer, uterine cancer, or ovarian cancer.
A composition for administration to a patient for the treatment of cancer, the composition comprising an effective amount of a combination of a topoisomerase inhibitor and a PARP inhibitor of formula (Ia):
- wherein R1, R2, R3, R4, and R5 are, independently selected from the group consisting of hydrogen, hydroxy, amino, nitro, iodo, bromo, fluoro, chloro, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl, and phenyl, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents are always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts, solvates, isomers, tautomers, metabolites, analogs or prodrugs thereof;
- wherein the cancer is not breast cancer, uterine cancer, or ovarian cancer.
A kit for treatment of cancer, comprising:
- (a) a PARP inhibitor of the formula (Ia):
- wherein R1, R2, R3, R4, and R5 are, independently selected from the group consisting of hydrogen, hydroxy, amino, nitro, iodo, bromo, fluoro, chloro, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl, and phenyl, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents are always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts, solvates, isomers, tautomers, metabolites, analogs or prodrugs thereof;
- and
- (b) a topoisomerase inhibitor;
- wherein the cancer is not breast cancer, uterine cancer, or ovarian cancer.
Dependencies are inferred from the claim text.